Senate Health Committee Plans To Codify FDA Generic Drug Proposal
This article was originally published in The Tan Sheet
Executive Summary
The Senate Health & Education Committee plans to codify FDA's Hatch/Waxman reform proposal after the final rule is issued
You may also be interested in...
Hatch/Waxman Reform Bill Needed Despite FDA Rule – McCain, Schumer
Legislation to reform the generic drug approval process will still be needed following issuance of FDA's final rule, Sens. John McCain (R-Ariz.) and Charles Schumer (D-N.Y.) said
Hatch/Waxman Reinterpretation Underpins Change In 30-Month Stay Policy
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Hatch/Waxman language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC